StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Lucentis (ranibizumab — Wet AMD, Ex-US) by Quarter

Lucentis (ranibizumab — Wet AMD, Ex-US) ($M)

QuarterlyAnnual

Novartis Lucentis (ranibizumab — Wet AMD, Ex-US): $87M in Q3 2026, down 41.2% from a year earlier. That is the lowest of the 35 quarters on record here.

Latest, Q3 2026
87
Period ended Sep 30, 2026
Change on a year earlier
-41.2%
148 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Lucentis | 87 | 148 | – 41 | – 41”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLucentis (ranibizumab — Wet AMD, Ex-US) ($M)Year on yearSource
Q3 2026Sep 30, 202687-41.2%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026126-27.2%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026104-45.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025133-36.7%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025148-39.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025173-37.1%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025189-39.8%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024210-30.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024245-32.5%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024275-30.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024314-24.5%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023301-24.4%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023363-20.2%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023395-21.2%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023416-20.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022398-21.7%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up lucentis (ranibizumab — Wet AMD, Ex-US)

Cite this data

StockData. (2026). Novartis Lucentis (ranibizumab — Wet AMD, Ex-US) ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lucentis

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.